Lmcg Investments LLC Lowers Position in Abbott Laboratories $ABT

Lmcg Investments LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 24.8% during the first quarter, HoldingsChannel.com reports. The fund owned 101,379 shares of the healthcare product maker’s stock after selling 33,374 shares during the quarter. Lmcg Investments LLC’s holdings in Abbott Laboratories were worth $10,409,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Virginia Wealth Management Group Inc. increased its stake in Abbott Laboratories by 7.1% in the 1st quarter. Virginia Wealth Management Group Inc. now owns 6,818 shares of the healthcare product maker’s stock worth $700,000 after acquiring an additional 453 shares during the last quarter. Jericho Financial LLP boosted its position in shares of Abbott Laboratories by 21.1% during the 1st quarter. Jericho Financial LLP now owns 33,685 shares of the healthcare product maker’s stock valued at $3,458,000 after acquiring an additional 5,867 shares during the last quarter. Eads & Heald Wealth Management grew its holdings in shares of Abbott Laboratories by 7.3% in the first quarter. Eads & Heald Wealth Management now owns 14,123 shares of the healthcare product maker’s stock valued at $1,450,000 after purchasing an additional 966 shares in the last quarter. WealthPLAN Partners LLC increased its position in Abbott Laboratories by 16.2% in the first quarter. WealthPLAN Partners LLC now owns 6,621 shares of the healthcare product maker’s stock worth $680,000 after purchasing an additional 924 shares during the last quarter. Finally, Bank of Stockton raised its stake in Abbott Laboratories by 13.8% during the first quarter. Bank of Stockton now owns 22,197 shares of the healthcare product maker’s stock valued at $2,279,000 after purchasing an additional 2,685 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ABT shares. JPMorgan Chase & Co. lowered their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Argus decreased their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Stifel Nicolaus lowered their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Finally, Jefferies Financial Group decreased their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.42.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by insiders.

Abbott Laboratories Trading Down 0.8%

ABT stock opened at $95.12 on Thursday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The stock has a market capitalization of $165.68 billion, a price-to-earnings ratio of 26.64, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61. The firm’s fifty day simple moving average is $89.15 and its two-hundred day simple moving average is $103.53.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter last year, the business earned $1.09 EPS. The business’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.6%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.